INTERNATIONAL PATENT: ASTRAZENECA AB FILES APPLICATION FOR "COMBINATION THERAPY COMPRISING DURVALUMAB AND CISPLATIN/GEMCITABINE FOR USE IN TREATING BLADDER CANCER"

GENEVA, Jan. 5 -- ASTRAZENECA AB (SE-151-85Sodertalje) filed a patent application (PCT/IB2025/056417) for "COMBINATION THERAPY COMPRISING DURVALUMAB AND CISPLATIN/GEMCITABINE FOR USE IN TREATING BLADDER CANCER" on Jun 24, 2025. With publication no. WO/2026/003724, the details related to the patent application was published on Jan 02, 2026.

Notably, the patent application was submitted under the International Patent Classification (IPC) system, which is managed by the World Intellectual Property Organization (WIPO).

Inventor(s): GUPTA, Ashok (MEDIMMUNE, LLCONE MEDIMMUNE WAYGAITHERSBURG, Maryland 20878), FERRO, Salvatore (ASTRAZENECA PHARMACEUTICALS LPONE MEDIMMUNE WAYGAITHERSBURG, Maryland 20878)

Abstract: The disclosure relates to method...